Rocatinlimab’s OX40-targeted therapy for severe atopic dermatitis: systemic gaps in clinical trial design and equity in treatment access
Original framing: “[Correspondence] Rocatinlimab atopic dermatitis in two global phase 3 clinical trials” — The Lancet
The original framing omits the historical exploitation of marginalized groups in clinical trials, the role of environmental racism in atopic dermatitis prevalence, and the lack of indigenous or traditional medicine perspectives in dermatological treatment. It also ignores the structural causes of treatment inequity, such as the high cost of biologics, the underrepresentation of Black and Latino patients in trials, and the lack of culturally competent care. Historical parallels to eugenics-era medical research are also overlooked.
Low structural omission detected in mainstream coverage.
The narrative is produced by academic-industrial complexes (e.g., Emma Guttman-Yassky’s team, funded by Amgen) for pharmaceutical stakeholders and elite medical institutions, reinforcing a biomedical model that centers drug efficacy over social determinants of health. The framing serves to legitimize high-cost biologic therapies while obscuring the role of profit motives in shaping treatment paradigms. It also deflects attention from systemic barriers like insurance denials, geographic disparities in specialist access, and the racial biases in dermatological diagnosis and care.
Black and Latino patients are underrepresented in atopic dermatitis trials despite higher prevalence and severity, reflecting systemic biases in recruitment and diagnosis. Low-income communities face barriers to accessing biologics due to cost and insurance denials, yet their lived experiences with alternative therapies are excluded from clinical guidelines. The trial’s design also overlooks the intersectional impacts of racism, poverty, and environmental exposure on disease progression.
Rocatinlimab’s phase 3 trials exemplify the biomedical-industrial complex’s focus on high-cost, high-margin therapies while systemic inequities in dermatology persist.